What Medicine Sermorelin Is
Medicine Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on Sermorelin and the broader GHRH (1-29) analog class. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any Sermorelin product or any other peptide. Our work is editorial commentary on publicly available science.
The word 'medicine' in the domain name is editorial framing — a position the publisher occupies relative to the clinical research literature, not a claim about the site's services. The framing is research-medicine: pituitary endocrinology, GHRH-receptor pharmacology, the pediatric the historical FDA-approved branded sermorelin trials of the 1990s, the adult somatopause work of Khorram and Vittone, the modern GH-secretagogue reviews. We read the literature in the register of scientific visualization, which is what the dark, luminescent design language reflects.
What We Publish
The site is built around the published Sermorelin record. The /research page is the substantive walk through mechanism, clinical trials, reported benefits, and comparative pharmacology within the GHRH-analog and GH-secretagogue classes. The /dosage page documents what doses were administered in published studies — pediatric 30 mcg/kg subcutaneously at bedtime in the international multi-site study group cohort 03, the 1 mcg/kg IV diagnostic provocative test 06, adult research doses including Khorram's 10 mcg/kg nightly for 16 weeks 09 — framed throughout as studied-at, not prescriptive.
The /side-effects page covers the safety profile reported in published trials, the standard contraindications, and the long-term safety record's honest gaps. The /faq page answers twenty-five of the most common Sermorelin questions with direct, cited answers. The /references page is the bibliographic anchor with every citation and its DOI or PubMed URL.
What We Don't Do
We do not sell Sermorelin or any peptide. We do not connect readers to suppliers, telehealth services, compounding pharmacies, or clinics. We do not make medical recommendations. We do not provide dosing instructions for personal use. We do not endorse any specific commercial product or formulation.
The FDA regulatory history of Sermorelin acetate — approved as the historical FDA-approved branded product in 1997 for pediatric idiopathic GH deficiency, voluntarily discontinued from the US market in 2008 for commercial (not safety) reasons 17 — is relevant context for any reader of the literature, but we are not a regulatory guide and we are not a substitute for the FDA Orange Book or for a qualified prescriber's judgment. Sermorelin and other GHRH analogs are also prohibited under WADA's S2 category for competitive athletes; this site documents that fact without commenting further on athletic-context use.
If you are looking for clinical guidance on growth hormone deficiency or any related condition, please consult an endocrinologist or your physician. If you are looking for the peer-reviewed Sermorelin literature, the published references page is the starting bibliography.
Editorial Method
Our editorial method is straightforward. We read the primary published Sermorelin literature — pediatric clinical trials, adult research, pharmacokinetic studies, comparative pharmacology, and modern GH-secretagogue reviews — and we summarize what each paper measured. Every quantitative claim on this site maps to a numbered citation in the references_index, and every citation links to a verifiable PubMed, DOI, or open-access URL. We do not invent findings. We do not extrapolate beyond what the studies report. Where a question has no published answer — adult phase 3 trial data for the Sermorelin moiety specifically, long-duration adult safety data — we name the gap rather than papering it over with speculation. Our editorial register is scholarly: term-first, attribution-after, precise where the data is precise and honest where it is not.
The site's visual language — dark medium, glowing recursive ornaments, luminescent typography — is a deliberate translation of the underlying physiology. Sermorelin's mechanism is bioluminescent in the literal biological sense: a recursive, pulsatile, self-similar release pattern amplified through a class B GPCR. The dark luminescent aesthetic registers that physiology as living complexity, in the register of scientific visualization rather than consumer marketing.